Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges
- PMID: 20369045
- PMCID: PMC2848745
- DOI: 10.4143/crt.2010.42.1.1
Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges
Abstract
A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase III clinical studies demonstrating which therapeutic approach, if any, would prolong life with no significant morbidity. Radiotherapy has been the main therapeutic modality with a curative potential for patients with post-RP PSA relapse. This review article depicts issues and challenges in the management of patients with post-RP PSA relapse, presents the literature data for the efficacy of salvage radiotherapy, either alone or in combination of androgen ablation therapy, and discusses future directions that can optimize treatment strategies.
Keywords: PSA relapse; Post radical prostatectomy; Salvage radiotherapy.
Similar articles
-
External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.Cancer J Sci Am. 1997 Mar-Apr;3(2):78-87. Cancer J Sci Am. 1997. PMID: 9099457
-
Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.Cancer J Sci Am. 1998 Sep-Oct;4(5):324-30. Cancer J Sci Am. 1998. PMID: 9815297 Clinical Trial.
-
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?J Nucl Med. 2014 Sep;55(9):1424-9. doi: 10.2967/jnumed.114.138313. Epub 2014 Jun 16. J Nucl Med. 2014. PMID: 24935990
-
PSA relapse prostate cancer: the importance of tailored therapy.Urol Oncol. 2004 Jan-Feb;22(1):62-9. doi: 10.1016/j.urolonc.2003.12.002. Urol Oncol. 2004. PMID: 14969807 Review.
-
[Adjuvant vs. salvage radiotherapy after radical prostatectomy].Aktuelle Urol. 2015 Jan;46(1):52-8. doi: 10.1055/s-0034-1395656. Epub 2015 Feb 6. Aktuelle Urol. 2015. PMID: 25658231 Review. German.
Cited by
-
Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study.J Radiat Res. 2015 Jul;56(4):750-6. doi: 10.1093/jrr/rrv027. Epub 2015 Apr 24. J Radiat Res. 2015. PMID: 25910489 Free PMC article.
-
Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.J Radiat Oncol. 2013 Sep 1;2(3):309-314. doi: 10.1007/s13566-013-0099-2. J Radiat Oncol. 2013. PMID: 24073305 Free PMC article.
-
Diospyros rhodocalyx Kurz induces mitochondrial-mediated apoptosis via BAX, Bcl-2, and caspase-3 pathways in LNCaP human prostate cancer cell line.PeerJ. 2024 Jul 1;12:e17637. doi: 10.7717/peerj.17637. eCollection 2024. PeerJ. 2024. PMID: 38966207 Free PMC article.
-
Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):206-13. doi: 10.1016/j.ijrobp.2016.04.023. Epub 2016 Apr 30. Int J Radiat Oncol Biol Phys. 2016. PMID: 27511856 Free PMC article. Clinical Trial.
-
Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.J Urol. 2014 May;191(5):1446-53. doi: 10.1016/j.juro.2013.10.065. Epub 2013 Oct 19. J Urol. 2014. PMID: 24144687 Free PMC article. Clinical Trial.
References
-
- Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393–1401. - PubMed
-
- Oesterling JE, Chan DW, Epstein JI, Kimball AW, Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766–772. - PubMed
-
- Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152:1358–1368. - PubMed
-
- Presti JC, Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998;52:1079–1084. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous